CALGARY,
AB, Aug. 30, 2022 /CNW/ - Nanalysis
Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1)
("Nanalysis" or the "Company") announces that the Company's Board
of Directors has granted a total of 377,500 stock options to its
employees, including 175,000 to an officer, pursuant to the
Company's stock option plan. Each option is exercisable to purchase
one common share in the capital of the Company at $1.10 per share for a period of five years from
the date of issuance. The options vest as to one-third on each of
the 12 month, 24 month and 36 month anniversary date of
grant.
About Nanalysis Scientific
Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV)
in Canada with ticker symbol 'NSCI', OTC and
the Frankfurt exchange under the ticker symbol '1N1'. The
company's business is what we term "MRI and NMR for industry". The
company develops and manufactures portable Nuclear Magnetic
Resonance (NMR) spectrometers or analyzers for laboratory and
industrial markets. The NMReady-60™ was the first full-feature
portable NMR spectrometer in a single compact enclosure requiring
no liquid helium or any other cryogens. The company has followed-up
that initial offering with new products and continues to have a
strong innovation pipeline. Nanalysis recently announced that it
has begun selling a 100MHz device in 2020. The Company's new device
will be the most powerful and most advanced compact NMR device ever
brought to market.
Nanalysis devices are used in many industries (oil and gas,
chemical, mining, pharma, biotech, flavor and fragrances,
agrochemicals, law enforcement, and more) as well as numerous
government and university research labs around the world. The
Company continues to exploit new global market opportunities
independently and with partners.
With the recent acquisition of K'Prime, the company maintains a
North American sales and service company of over 40 individuals who
cover scientific instrumentation for pharma, food, chemical and oil
& gas customers, as well as imaging systems for security
applications.
Additionally, the Company has a 43% ownership in Quad Systems AG
("Quad Systems"), with an option to purchase the remaining shares.
Quad Systems is a Zurich-based Nuclear Magnetic Resonance
(NMR) company focused on high-field NMR for pharmaceutical and
other vertical markets.
Notice regarding Forward Looking
Statements and Legal Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanalysis-scientific-corp-announces-grant-of-stock-options-301615057.html
SOURCE Nanalysis Scientific Corp.